Phase II Trial of the combination of Paclitaxel and 5-Fluorouracil in the Treatment of Advanced Gastric Cancer ? A Novel, Safe, and Effective Regimen
Andre M. Murad, Andy Petroianu, Rodrigo C. Guimaraes, et al.
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001
Reviewers: Li Liu, MD Source: American Journal of Clinical Oncology, 22(6):580-586, December 1999.
Précis: So far, the combination of paclitaxel and 5-fluorouracil have appeared to be very effective and safe in patients with advanced gastric cancer. More studies are necessary.
Gastric cancer is the 9th leading cause of cancer related death in the United States, and second in the world. Curative surgery is the mainstay of treatment whenever the tumor is resectable. Adjuvant therapies have been investigated extensively for more than 30 years. Dr. Andre M. Murad and colleagues from Hospital das Clinicas in Brazil conducted this phase II study to explore the activity and efficacy of the combination of paclitaxel and 5-fluorouracil (5-FU) in the treatment of advanced gastric adenocarcinoma.
A total of 31 patients with locally unresectable or metastatic gastric carcinoma received up to 7 cycles of paclitaxel and 5-FU. 29 patients were eligible for response and toxicity evaluation.
At 4 months, 24.1% of patients had complete responses and 41.4% had partial responses, and 51% of patients had improvement in quality of life.
There were no serious toxicities or deaths associated with this treatment.
The combination of paclitaxel and 5-fluorouracil appeared to be very effective and safe in patients with advanced gastric cancer. Phase III randomized studies are warranted to confirm the real merit of this novel regimen.
Sep 11, 2014 - For heavily pretreated, advanced ovarian cancer patients, an oral tablet inhibitor of poly ADP ribose polymerase, olaparib, can be safely administered with a weekly carboplatin/paclitaxel regimen, according to a phase I study presented at the Marsha Rivkin Center for Ovarian Cancer Research-AACR Ovarian Cancer Research Symposium, held Sept. 8 to 9 in Seattle.